Phio Pharmaceuticals Corp. (PHIO) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $1.05. The rating moved from Overbought to Neutral on August 19, 2026.

• Public ratingNeutral (as of August 19, 2026)
• Last close$1.05
• Last changeMoved from Overbought to Neutral on August 19, 2026
• SectorHealthcare
• IndustryBiotechnology

AI analysis

Phio Pharmaceuticals is a small-cap, pipeline-centric biopharma where valuation is driven by clinical progress and financing access. The company faces the typical early-stage risks of limited revenue, potential dilution, and sensitivity to trial outcomes, offset by sector tailwinds for biologics/oligonucleotide technologies and possible partnership interest. Near-term movement will be news-driven and liquidity-constrained; outcomes from clinical updates or corporate deals are the main catalysts that could materially change the outlook.

Key factors

• Early-stage biopharmaceutical profile with pipeline-driven valuation — near-term clinical readouts and partnership activity are primary value drivers
• Limited or no meaningful product revenue; financial health likely dependent on cash runway and access to capital markets
• Sector thematic tailwinds for biologics and RNA/oligonucleotide technologies could improve partner interest and CDMO demand
• Market sentiment is cautious but modestly risk-on in equities; biotech small-caps remain sensitive to macro and funding conditions
• Low liquidity and small market cap amplify price moves around news, increasing short-term volatility

Risks

• Clinical or regulatory setbacks in one or more pipeline programs that would materially reduce future prospects
• Cash runway constraints leading to equity dilution or unfavorable financing terms
• Intense competition from larger, better-funded biopharma firms and platform companies
• Low trading liquidity producing exaggerated moves on limited news or block trades
• Adverse macro environment or tighter funding markets reducing partnership or M&A interest
• Unfavorable changes in reimbursement, pricing, or policy that affect commercialization potential

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.